Chronic Lymphocytic Leukemia Market Size Worth USD 21.22 Bn in 2032 | Emergen Research
05 déc. 2023 09h17 HE
|
Emergen Research
Vancouver, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The global chronic lymphocytic leukemia (CLL) market, valued at USD 10.00 Billion in 2022, is poised for substantial growth with a projected revenue...
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting
12 déc. 2022 17h30 HE
|
Nurix Therapeutics, Inc.
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK...
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
26 mai 2022 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has...
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
30 sept. 2021 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
05 avr. 2021 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
07 déc. 2020 10h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation...
Imbruvica Market will grow at a CAGR of 26.5% to hit $31,773.4 Million by 2025 - Analysis by Trends, Size, Share, Price, Growth Drivers and Business Opportunities: Adroit Market Research
10 mai 2019 01h33 HE
|
Adroit Market Research
Dallas,Texas, May 10, 2019 (GLOBE NEWSWIRE) -- The global Imbruvica market is projected to witness significant growth, rising with a CAGR of 26.5% over the forecast period. The market is projected...
From Nurse to Patient
06 févr. 2014 17h44 HE
|
Genentech
MISSION, KS--(Marketwired - Feb 6, 2014) - (Family Features) Despite her career as a scrub nurse for general cancer surgeries, a personal diagnosis of cancer still came as a surprise.
"It...